Figure 8.

MTL-CEBPA Promotes CD8⁺ T Lymphocytes and CD16⁺ Granulocytes in an LPS-Stimulated Humanized NSG Model

As described in Figure 6A, cells from PB and BM were collected for flow cytometric analysis. (A) MTL-CEBPA increased human CD45⁺ cells in PB. It did not affect (B) human CD4⁺ T cell subset, but (C) increased human CD8⁺ T cell subset in PB. MTL-CEBPA reduced the LPS-induced increase of (D) PD-1⁺ CD4⁺ and (E) PD-1⁺CD8⁺ T lymphocyte subsets in PB. MTL-CEBPA activated the (F) human CD25⁺, (G) CD69⁺, and (H) CD45RO⁺ T lymphocyte subsets. MTL-CEBPA treatment had no significant impact on (I) CD14⁺ monocyte or (J) CD11b⁺ CD14⁺ macrophage subset in PB. It promoted the (K) CD16⁺ granulocyte and (L) CD10⁺CD16⁺CD14⁻ neutrophil subsets in PB. (M) MTL-CEBPA reduced human CD45⁺ cells in BM. (N) MTL-CEBPA did not significantly change the human CD4⁺ T lymphocyte subset, but (O) it increased the human CD8⁺ T lymphocyte subset in BM. It increased the (P) PD-1⁺ CD4⁺ T lymphocyte and (Q) PD-1⁺CD8⁺ T lymphocyte subsets in BM. It also activated T lymphocytes in BM: (R) human CD25⁺, (S) CD69⁺, and (T) CD45RO⁺ subsets. MTL-CEBPA treatment expanded the (U) human CD14⁺ monocyte and (V) CD11b⁺CD14⁺ macrophage subsets and the (W) CD16⁺ granulocyte and (X) CD10⁺CD16⁺CD14⁻ neutrophil subsets in bone marrow. Each determination analysis was performed in duplicate. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, no significant difference. Analysis by two-tailed Student’s t test.